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Abstract
Background: There have been few reports of long-term survival of HIV-infected patients on antiretroviral therapy
(ART) in Africa managed under near normal health service conditions.
Methods: Participants starting ART between February 2005 and December 2006 in The AIDS Support (TASO) clinic
in Jinja, Uganda, were enrolled into a cluster-randomised trial of home versus facility-based care and followed up
to January 2009. The trial was integrated into normal service delivery with patients managed by TASO staff
according to national guidelines. Rates of survival, virological failure, hospital admissions and CD4 count over time
were similar between the two arms. Data for the present analysis were analysed using Cox regression analyses.
Results: 1453 subjects were enrolled with baseline median count of 108 cells/μl. Over time, 119 (8%) withdrew
and 34 (2%) were lost to follow-up. 197/1453 (14%) died. Mortality rates (95% CI) per 100 person-years were 11.8
(10.1, 13.8) deaths in the first year and 2.4 (1.8, 3.2) deaths thereafter. The one, two and three year survival
probabilities (95% CI) were 0.89 (0.87 - 0.91), 0.86 (0.84 - 0.88) and 0.85 (0.83 - 0.87) respectively. Low baseline CD4
count, low body weight, advanced clinical condition (WHO stages III and IV), not being on cotrimoxazole
prophylaxis and male gender were associated independently with increased mortality. Tuberculosis, cryptococcal
meningitis and diarrhoeal disease were estimated to be major causes of death.
Conclusion: Practical and affordable interventions are needed to enable earlier initiation of ART and to reduce
mortality risk among those who present late for treatment with advanced disease.
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Background
Antiretroviral therapy (ART) has been scaled-up rapidly.
About 4 million people in Africa are now on ART [1].
Various studies have shown that mortality during the
first 6 months or so after initiating ART is much higher
than in developed countries and retention of patients in
programmes is poor [2,3]. However, most longitudinal
studies conducted in Africa have been either short-term
or have involved small numbers of participants. A recent
randomised trial conducted in Uganda and Zimbabwe
comparing clinical with laboratory driven monitoring
found very high and similar 5-year survival rates in the
two trials arms of 87% and 90% respectively [4]. How-
ever, the participants had good access to care and were
managed in research clinics by dedicated physicians.
Much less is known about long-term survival on antire-
troviral therapy under normal health service conditions
where access to care is more difficult and the quality
and level of clinical support is lower.
Understanding the temporal sequence and causes of
death of patients on ART is vital to inform intervention
strategies, but most deaths occur at home and cause of
death is not determined. There is little understanding of
the causes of death of people on ART in Africa. Here
we report on the mortality rates of participants followed
in an ART programme in a normal health service
* Correspondence: shabbar.jaffar@lshtm.ac.uk
4Faculty of Epidemiology and Population Health, London School of Hygiene
and Tropical Medicine, UK
Full list of author information is available at the end of the article
Amuron et al. AIDS Research and Therapy 2011, 8:39
http://www.aidsrestherapy.com/content/8/1/39
© 2011 Amuron et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
setting in Jinja, SE Uganda, together with the estimated
causes of deaths from verbal autopsies.
Methods
The study was based at The AIDS Support Organisation
(TASO) clinic in Jinja, South East Uganda. TASO is a
large non-governmental organisation (NGO) which pro-
vides care and support to people living with HIV/AIDS.
Participants were enrolled in a cluster-randomised trial
comparing home-based HIV care with facility care [5].
All adult patients (18 years old or more) living within
the TASO catchment population and initiating on ART
were invited to join and enrolled consecutively. The trial
was integrated into normal health service delivery [5-7].
Trial participants were managed identically to non-trial
patients by TASO staff using national guidelines.
Enrolment was done between February 2005 and
December 2006 and participants were followed up till
31st January 2009. The trial showed that participants in
the home and facility care arms had similar rates of sur-
vival, virologic failure, CD4 count recovery, and reported
adherence and the costs incurred by the health service
were marginally lower in the home-care arm. Just 24/
1477 (1.6%) had refused to join the trial. Details of the
two arms are published elsewhere [5]. In brief, in the
home-based care arm, field officers travelling on motor-
bikes delivered drugs to the homes of study participants
and provided adherence support. Participants were
assessed using a checklist and referred to the clinic if
necessary. A single repeat home-visit was done for those
not found at home, usually 1-2 days after the appoint-
ment date. In the facility arm, patients were asked to
come monthly to clinic to pick up their drugs. On each
visit they were reviewed by a nurse, received adherence
counselling and were referred to a physician if neces-
sary. Those who failed to attend clinic were usually vis-
ited at home 1-2 days after the appointment date and
reminded to attend. Routine clinic visits were scheduled
at 2, 6 months after starting ART and 6-monthly there-
after in the home arm and at 2, 3 and 3-monthly there-
after in the facility arm. At each of these visits,
participants were reviewed by a counsellor and a physi-
cian. Participants in both arms were asked to self-refer
at any time they felt unwell. They were declared as lost-
to-follow-up if their whereabouts were not known on at
least 2 occasions one month apart. Routine CD4 count
testing was done 6-monthly for all trial participants.
Deaths were detected from TASO records or through
home visits. A research physician visited the homes of
the deceased, usually more than two months after the
death, and collected information on the events, signs
and symptoms leading up to the death. Any available
medical records were also collected. Two research physi-
cians independently reviewed the information and
assigned the probable cause of death. These records
were reviewed by a senior independent physician from
the government referral hospital to confirm the diag-
noses or to resolve discrepancies.
Participants who moved out of the area were with-
drawn from the study. Their survival status was ascer-
tained between November 2008 and January 2009
through TASO records and home visits. The trial was
approved by the institutional review boards of the
Uganda Virus Research Institute, London School of
Hygiene and Tropical Medicine, US Center for Disease
Control and Prevention and the Uganda National Coun-
cil of Science and Technology.
Statistical Analysis
Survival analysis methods were used to analyze the time
to death. Subjects who did not die were regarded as
being censored on the day that they were last seen or
the date of withdrawal or loss to follow-up (unless it
was established that a subject who withdrew or was lost
to follow-up had later died, in which case they were
treated as having died on the date of death recorded
during tracing). In order to explore factors associated
with mortality, unadjusted mortality rates together with
95% confidence limits were calculated for each level of
the potential exposures and confounders. For the pur-
pose of this descriptive analysis only, continuous covari-
ates were converted to categorical variables.
Factors were considered as risk factors or confounders
in models on substantive grounds i.e. on the basis of
prior knowledge or biological plausibility [8]. The expo-
sures considered were baseline WHO stage, baseline
CD4 count, baseline weight, baseline haemoglobin,
whether or not the patient was on cotrimoxazole pro-
phylaxis at baseline, baseline log10 viral load and study
arm. Sex and age were regarded as potential confoun-
ders of the relationship between risk factors such as
CD4 count and mortality. Although the primary analysis
of the cluster randomised trial showed no difference in
mortality rates between the two study arms, we did
investigate study arm as an exposure. In order to evalu-
ate the effect of these explanatory variables, both unad-
justed and adjusted Cox proportional hazards regression
models were fitted. The models were fitted using robust
standard errors to take into account the clustering of
subjects in the study design. Since the number of candi-
date explanatory variables was small, all were included
in the final model. Random effects Poisson models were
then fitted as a consistency check. Age, weight, CD4
count, haemoglobin and log10 viral load were treated as
continuous covariates and fractional polynomials [9]
were used to test for nonlinearity (only CD4 count
showed nonlinearity and a first order square root trans-
formation fractional polynomial was found to be
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optimal). Continuous covariates were scaled in order to
simplify interpretation of the results. Further Cox
regression models were fitted treating CD4 count (again
subject to a square root transformation), weight and
cotrimoxazole prophylaxis as time varying covariates, to
ascertain whether this changed the interpretation com-
pared to the use of the baseline values. All analyses
were carried out using Stata release 10.1 (Statacorp.
2007).”
Results
1453 subjects were enrolled. Table 1 shows the baseline
characteristics. The majority (71%) were women, the
median age was 38 years and the median CD4 count
was 108 cells/μl. 938 (64.6%) had a baseline viral load of
100,000 copies/ml or more and 791 (54%) were at
WHO clinical stage III or IV.
119 (8%) trial subjects withdrew from the trial and 34
(2%) were lost to follow-up. The reasons for the with-
drawals were: 53(4%) left the area for employment, 25
(2%) changed to a provider closer to their home, 20(1%)
could no longer afford transport money for clinic visits,
19(1%) feared disclosure of their HIV status, 1 withdrew
after developing side effects to ART and 1 claimed to
have been healed spiritually. The median (IQR) time to
withdrawal was 350 days (147 - 609). The survival status
of the participants who withdrew from the trial was as
follows: three (3%) had died, 98 (82%) were on ART
with various other providers, 1 (1%) was alive and not
on ART and 17 (15%) were no longer in contact with
TASO.
Overall, 197/1453 (14%) trial participants died. During
the first year, 154/1453 (11%) died and the mortality
rate was 11.8 deaths (95% CI 10.1, 13.8) per 100 person-
years. By 12 months, 1168 subjects were alive and under
follow-up. Forty-three (4%) died after 12 months and
the mortality rate was 2.4 deaths (95% CI 1.8, 3.2) per
100 person-years. The one, two and three year survival
probabilities (95% CI) were 0.89 (0.87 - 0.91), 0.86 (0.84
- 0.88) and 0.85 (0.83 - 0.87) respectively (Figure 1).
Table 2 shows the mortality rates broken down by the
potential explanatory variables. Mortality was higher for
males than for females, for those with baseline CD4 cell
counts below 50 cells/μl, weight below 50 kg at baseline,
baseline Hb below 6.5 g/dl, not on cotrimoxazole pro-
phylaxis and increased with increasing baseline WHO
stage. Mortality did not differ between the two study
arms.
Table 3 shows the results of fitting unadjusted and
adjusted Cox regression models to find factors asso-
ciated with mortality. Baseline WHO stage, CD4 count,
Table 1 Baseline social and demographic characteristics
of the study population
Number in study 1453
Study arm, number (%)
Facility 594 (41)
Home 859 (59)
Women, number (%) 1031 (71)
Age in years, median (IQR) 38 (32-44)
Education level, number (%)
No education 234 (16)
Primary 816 (56)
Secondary/tertiary 403 (28)
Clients’ main occupation, number (%)









CD4 cell count cells/μl at enrolment, number (%)
< 50 444 (30)
50-99 232 (16)
100-200 654 (45)
> 200 123 (9)
Median (IQR) cells/μl 108 (35-165)
Plasma viral load copies/ml, number (%)




> = 1,000,000 106
Median (IQR), copies/ml 163,224
(63,616-370,412)
On cotrimoxazole prophylaxis, number (%) 1403 (97%)
Haemoglobin g/dl, number (%) *
≥ 11 701 (48%)
9.5 - 10.9 407 (28%)
8.0 - 9.4 242 (17%)
6.5 - 7.9 80 (6%)
< 6.5 19 (1%)
Median g/dl (IQR) 10.9 (IQR 9.5 - 12.3)
Weight, kg, number (%)
< 50 431 (30%)
50-60 698 (48%)
> 60 317 (22%)
Mean kg (sd) 54.2 (9.2)
Haemoglobin missing for 4 subjects. Weight missing for 7 subjects.
IQR = inter-quartile range; sd = standard deviation
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weight, cotrimoxazole prophylaxis and gender were inde-
pendent predictors of mortality. After adjusting for these
factors, baseline viral load, age, Hb level and study arm
were not associated with mortality. Using WHO stage II
as a baseline (due to the small number of patients classi-
fied as WHO stage I), patients at WHO Stage III and IV
were at increased risk. One unit increase in the trans-
formed CD4 count led to a 39% decrease in risk of death;
such a unit increase corresponds to an increase in CD4
count from 0 to 25, or from 25 to 100, or from 100 to
225; thus the effect of CD4 count is most pronounced at
low CD4 counts. A 5 kg increase in baseline weight led
to a 23% reduction in the risk of death. The risk of death
for patients not on cotrimoxazole prophylaxis was 2.2
times the risk for patients on cotrimoxazole prophylaxis.
The risk of death for females was 41% lower than the risk
for males and the risk of death increased by 9% for every
10 year increase in age at baseline. The proportional
hazards assumption in the Cox regression model was
tested using the test of Grambsch and Therneu, and
there was no evidence against the assumption (global
chi-square 15.53 on 11 df, P = 0.16).
Sensitivity analyses were done to assess the impact of
including study arm in the final model and assess the
effect of using random effects Poisson models, as was
done in the primary analysis of the cluster randomized
trial. Including study arm in the model and fitting a ran-
dom effects Poisson regression had a negligible effect (e.
g. the aHR for the effect of a one unit change in the
transformed CD4 count changed from 0.61 in the origi-
nal model to 0.60 when including study arm in the
model, while the adjusted rate ratio from the random
effects Poisson model was 0.59).
Overall 130/197 deaths occurred among subjects with
at most one CD4 count taken at baseline. Overall, 1276
(88%) subjects had two or more CD4 counts. Of these,
1213 (95%) had increases in CD4 count and of these, 54
(4%) died. Sixty-three (5%) had a drop in CD4 count
and 13 (21%) of these died. Among these 13 deaths, the
median drop was 45 cells/μl (IQR 29 - 101) and the
decline occurred within the first year in 8 (61.5%) of
these cases. Among the 50/63 who survived, the median
drop was 34 cells/μl (IQR 16 - 63) and the decline
occurred within the first year in seven cases (14%). In
an adjusted analyses, CD4 count fitted as a time-varying
covariate only had a negligible effect (the aHR for a one
unit change on the transformed scale was 0.59)
Verbal autopsies suggested that the most common causes
of death identified were: CNS infections (n. 25, 13%), diar-
rheal disease with dehydration (n. 25, 13%), tuberculosis (n.
22, 11%) and acute febrile illness (n. 22, 11%) (Table 4).
Verbal autopsies could not be done for 31 participants:
relatives had moved away and could not be traced in 29
cases and there was insufficient information on which to
make a diagnosis for 2 cases. There were no striking differ-
ences in the estimated causes of deaths between those
which occurred within 6-months of ART initiation and
which occurred later, although numbers were small.
Discussion
In this trial, which was integrated into normal health
service delivery in Uganda, the mortality rate was almost
Figure 1 Overall survival over a 42 month duration of follow up in the study
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12 deaths per 100 person-years in the first year follow-
ing ART initiation, five-fold higher than in subsequent
years. Indeed from 12 months onwards, the mortality
rate in our cohort was only slightly higher than that
reported in developed countries [10]. Other studies have
reported between 8 and 26% of patients dying within
the first year of starting ART [2]. The mortality rate in
the large DART was lower, with 5-year survival of 87%
and 90% in the clinically driven monitoring versus
laboratory and clinical monitoring arms respectively.
However, participants in this study had better access to
clinical care. The problem in Africa lies with the very
high early mortality. We have previously shown an even
higher mortality rate, around 30 deaths per 100 person-
years, during the pre-treatment screening period [11] in
this population and recent reviews show 32% loss to fol-
low-up during this pre-treatment period despite eligibil-
ity for ART [12], a 20% loss to follow-up among
patients within the first year of antiretroviral therapy
[13], among whom mortality is very high [14]. Taken
together, these findings suggest that the major problem
is early mortality and that mortality after 12 months in
Table 2 Mortality rates by potential baseline risk factors
Factor Level n Deaths Mortality rate per 100 person-years (95% C.I.)
Sex Male 422 69 8.0 (6.3; 10.2)
Female 1031 128 5.7 (4.8; 6.8)
Age ≤ 30 251 41 8.7 (6.4; 11.8)
31 to 40 670 83 5.8 (4.7; 7.2)
> 40 532 73 6.2 (4.9; 7.7)
WHO stage I 20 1 2.3 (0.3; 16.0)
II 642 55 3.8 (2.9; 5.0)
III 673 109 7.8 (6.5; 9.4)
IV 118 32 14.9 (10.5; 21.0)
Baseline CD4 count cells/mm3 <50 444 110 13.0 (10.8; 15.6)
50-99 232 20 3.9 (2.5; 6.0)
100 - 149 306 33 4.9 (3.5; 6.9)
150 - 199 339 21 2.8 (1.8; 4.2)
≥ 200 132 13 4.5 (2.6; 7.7)
Baseline plasma viral load copies/ml <1,000 21 3 6.7 (2.2; 20.7)
1,000 - 9,999 40 2 2.6 (0.6; 10.3)
10,000 -99,999 454 49 4.9 (3.7; 6.5)
100,000 -999,999 832 130 7.4 (6.3; 8.8)
>1,000,000 106 13 5.7 (3.3; 9.9)
Weight (kg) * < 50 431 94 11.0 (9.0; 13.4)
50 - 60 698 76 5.0 (4.0; 6.3)
> 60 317 22 3.0 (2.0; 4.6)
Haemoglobin (g/dl) ≥ 11 701 76 5.0 (4.0; 6.3)
9.5 - 10.9 407 64 7.4 (5.8; 9.5)
8.0 - 9.4 242 37 7.4 (5.3; 10.2)
6.5 - 7.9 80 12 6.7 (3.8; 11.7)
<6.5 19 6 19.2 (8.6; 42.8)
Missing 4 2
On cotrimoxazole prophylaxis Yes 1403 185 6.2 (5.3; 7.1)
No 50 12 12.0 (6.8; 21.1)
Study Arm Facility Based 594 80 6.5 (5.2; 8.1)
Home Based 859 117 6.3 (5.2; 7.5)
Time following initiating ART 0 - 5 months 1453 112 16.5 (13.7; 19.8)
6 - 11 months 1296 42 6.7 (5.0; 9.1)
12 - 23 months 1168 32 3.0 (2.2; 4.3)
24 - 35 months 872 8 1.3 (0.7; 2.6)
≥ 36 months 314 3 2.4 (0.8; 7.6)
* Weight was missing for 7 people of whom 5 died.
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well functioning programmes will be low. We believe
our findings are robust. Very few individuals refused to
join the study, the loss-to-follow-up was low and the
mortality rate among subjects who withdrew was similar
to those who were retained in care.
Patients in Africa generally present late for HIV treat-
ment with CD4 count typically well below 200 cells per
microlitre [15], as was the case in our study. Much of
the mortality in our study was attributed to tuberculosis,
cryptococcal meningitis and diarrhoea and clearly some
of this could have been prevented had patients initiated
ART earlier. However earlier ART initiation will not be
a reality for many because of the costs and difficulties of
accessing care, particularly for chronic conditions such
as HIV which require regular contact with health ser-
vices. We have previously shown that a single visit to
the clinic in our area costs 13% of a man’s and 20% of
woman’s monthly salary and that the cost of transport is
a major factor inhibiting patients starting ART [5].
There is therefore an urgent need to identify practical
Table 3 Unadjusted and adjusted Cox regression models for baseline factors associated with time to death
Factor Level Unadjusted HR (95% c.i.) Adjusted HR (95% c.i.) Adjusted P-value
Sex Male 1 (ref. level) 1 (ref. level) 0.002
Female 0.73 (0.52; 1.02) 0.59 (0.44; 0.80)
Study Arm Facility 1 (ref. level) 1 (ref. level)
Home-based 1.003 (0.77; 1.31) 0.92 (0.70; 1.20) 0.56
Age Per 10 year increase 1.002 (0.84; 1.20) 1.09 (0.91; 1.31) 0.30
WHO stage I 0.58 (0.08; 4.0) 0.72 (0.12; 4.42) 0.009
II 1 (ref. level) 1 (ref. level)
III 1.99 (1.57; 2.53) 1.41 (1.09; 1.83)
IV 3.64 (2.53; 5.23) 2.23 (1.45; 3.43)
√CD4/25 Per transformed CD4 increase * 0.52 (0.44; 0.61) 0.61 (0.51; 0.73) < 0.001
Log10 plasma viral load Per 1 log increase 1.15 (1.004; 1.31) 1.04 (0.91; 1.18) 0.51
Weight Per 5 kg increase 0.74 (0.67; 0.82) 0.77 (0.70; 0.85) < 0.001








* Because of the CD4 count transformation, per unit increases here means an increase in CD4 count from 0 to 25, or from 25 to 100, or from 100 to 225 etc;
Table 4 Causes of death overall and stratifed by when the death occurred after initiation of ART, number (%)
Overall Deaths < 6 months Deaths ≥ 6 months
Cause of Death
Central nervous system infections 25 (13) 19(17) 6(7)
Diarrheal disease with dehydration 25 (13) 17(15) 8(10)
Tuberculosis 22 (11) 13(12) 9(11)
Acute febrile illness 22 (11) 14(12) 8 (10)
Poor feeding/starvation 14 (7) 8(7) 6(7)
Anaemia 13 (7) 8 (7) 5 (6)
Septicemia 13 (7) 7 (6) 6 (7)
Pneumonia 7 (4) 3(3) 4(5)
Hemorrhage 5 (3) 2(2) 3(4)
Cardiovascular Disease 4 (2) 2(2) 2(2)
Kaposi’s Sarcoma 4 (2) 4(4) 0(0)
Trauma/accidents 3 (2) 1(1) 2(2)
Liver failure 3 (2) 0(0) 3(4)
Suicide 2 (1) 1(1) 1(1)
Other 4 (2) 2(2) 2(2)
Unknown 31 (16) 12(11) 19(23)
Total 197 113 84
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interventions which will reduce early mortality among
the many patients who will continue to present with
advanced HIV associated disease for the foreseeable
future.
Our study also identified several factors associated
independently with mortality. As expected low baseline
CD4 count and WHO clinical stage III or IV were asso-
ciated independently with increased mortality; but there
was no association with plasma viral load. Most patients
who died had only one CD4 count measured at baseline.
Among those in whom CD4 count was measured more
than once, mortality risk was more than 5-fold higher
among patients who had falls in their CD4 count than
those in whom CD4 count increased. However, fitting
CD4 count as a time-varying covariate did not signifi-
cantly improve the fit of the model compared to fitting
CD4 count at baseline. Although our numbers were
small, this accords with the findings of the DART trial
[4] which showed limited additional value of CD4 count
monitoring over clinical monitoring. More research is
needed to assess the costs and benefits of long-term
CD4 count monitoring in settings where access to care
is limited.
Men presented at a similar WHO stage and CD4
count as women but had significantly higher plasma
viral loads. After adjusting for these and the other fac-
tors including whether on cotrimoxazole prophylaxis
and weight, men had a much higher mortality than
women. Why this is so is puzzling. We know that in
most settings, fewer men access antiretroviral services
[13,16]. One explanation for their higher mortality could
be that men maintain less contact with health services
and have poorer adherence to treatment. This needs
further investigation in other cohorts. If true, it points
to a poor prognosis for men: fewer start antiretrovirals
and those who do may have poorer outcomes.
In conclusion, our study shows that under conditions
of normal health services the high early mortality of
HIV infected patients starting antiretroviral therapy is
associated with low baseline CD4 count, body weight,
advanced clinical conditions (WHO stages III and IV),
not being on cotrimoxazole prophylaxis and male gen-
der. Practical and affordable interventions are needed to
enable earlier initiation of ART and to reduce mortality
risk among those who present late for treatment with
advanced disease.
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